About Gongwin Biopharm Holdings

About company

Gongwin Biopharm Holdings, Co., Ltd. Cayman (Gongwin-KY; ticker: 6617) founded in 2014 is a Taiwan-based clinical-stage biopharmaceutical company focused on developing novel anti-cancer drugs. they adopt an innovative anti-tumor therapy called “minimally-invasive targeted tumor ablation” (MITTA) therapy for the treatment of focal malignancies. In 2017, Gongwin-KY has been granted “Biotech New Drug Company” designation by MOEA, Taiwan and became a public trading company at Taipei Emerging Stock Board.